Lyubimova N V, Pashkov M V, Tyulyandin S A, Gol'dberg V E, Kushlinskii N E
N. N. Blokhin Russian Oncological Center, Russian Academy of Medical Sciences, Moscow.
Bull Exp Biol Med. 2004 Jul;138(1):77-9. doi: 10.1023/b:bebm.0000046945.95479.d6.
Serum activity of tartrate-resistant acid phosphatase 5b (TRAP 5b) in patients with breast cancer and prostate cancer having bone metastases was much higher than in healthy donors and patients without skeletal injuries. TRAP 5b activity in patients with breast cancer and multiple bone metastases surpassed that in patients with single bone metastases. The mean activity of TRAP 5b and range of enzyme activity in women treated with bisphosphonates were significantly lower than in patients not receiving antiresorptive therapy. Diagnostic sensitivity and specificity of TRAP 5b as a marker of skeletal metastases in patients with breast cancer were 82 and 87%, respectively. In patients with prostate cancer these indexes were 71 and 83.4%, respectively. Detection of this marker in tumor patients holds much promise for early diagnostics of bone metastases, estimation of the severity of skeletal metastases, and monitoring of the efficiency of bisphosphonate therapy.
患有骨转移的乳腺癌和前列腺癌患者血清抗酒石酸酸性磷酸酶5b（TRAP 5b）活性远高于健康供体和无骨骼损伤的患者。乳腺癌伴多发骨转移患者的TRAP 5b活性超过单发骨转移患者。接受双膦酸盐治疗的女性患者中TRAP 5b的平均活性及酶活性范围显著低于未接受抗吸收治疗的患者。TRAP 5b作为乳腺癌患者骨转移标志物的诊断敏感性和特异性分别为82%和87%。在前列腺癌患者中，这些指标分别为71%和83.4%。在肿瘤患者中检测该标志物对骨转移的早期诊断、骨转移严重程度的评估以及双膦酸盐治疗效果的监测具有很大前景。
